Protagonist Therapeutics stock gains as Bank of America builds a sizable stake

Protagonist Therapeutics stock (ISIN US74374T1097) opened at USD 143.70 on Nasdaq on September 18, 2026, leaving the shares within striking distance of their 52-week high of USD 160.81 and valuing the biotech at USD 9.30 billion.

Bank of America takes a 2.05 percent stake

According to MarketBeat on September 18, 2026, Bank of America Corp DE disclosed that it had acquired 1,324,498 Protagonist Therapeutics shares, a position valued at approximately USD 162,357,000 based on recent prices and representing about 2.05 percent of the company.

The same filing overview notes that institutional investors collectively hold around 98.63 percent of Protagonist Therapeutics, underscoring that the stock is largely in professional hands and that the new stake from Bank of America adds another large-scale holder to the register.MarketBeat

For equity investors, the size of the Bank of America position is notable: the 1,324,498 shares mentioned in the filing imply that the bank has committed more than USD 160 million to the name and now ranks among the larger individual holders of the stock.MarketBeat

Analyst sentiment and price targets remain supportive

Alongside the fresh institutional interest, analyst coverage of Protagonist Therapeutics remains broadly positive, with the stock carrying a consensus rating of Moderate Buy as of mid-September 2026.

According to MarketBeat on September 18, 2026, sixteen research analysts currently rate Protagonist Therapeutics stock Buy and two rate it Hold, producing the Moderate Buy consensus and an average price target of USD 147.13.

The same analyst overview shows a range of price targets, with a high target of USD 190.00 and a low target of USD 82.00, indicating differing views on upside but a clear bias toward positive recommendations.MarketBeat

In one individual case, BMO Capital Markets recently increased its price target on Protagonist Therapeutics from USD 178.00 to USD 190.00 while maintaining an outperform rating, as reported in the same MarketBeat summary on September 1, 2026; this move lifted the top end of the published target range and underlined the positive stance taken by that house.MarketBeat

Valuation, trading range and risk signals

With the shares opening at USD 143.70 on September 18, 2026 and a consensus price target at USD 147.13, the implied upside versus the analyst average is modest at around 2.4 percent, suggesting that much of the current positive view is already reflected in the valuation.MarketBeat

The same data set indicates that Protagonist Therapeutics trades on a price-earnings ratio of 139.52 based on recent figures, a level that puts the stock firmly into growth territory and highlights the degree to which investors are pricing in future expansion rather than near-term profits.MarketBeat

Per the same MarketBeat overview dated September 18, 2026, the stock has a 52-week low of USD 58.91 and a 52-week high of USD 160.81, meaning that the opening level of USD 143.70 sits more than twice the 52-week low and within roughly 11 percent of the high, underscoring the strong run the shares have delivered over the past year.MarketBeat

The same profile lists a beta of 1.80 for Protagonist Therapeutics, indicating that the stock has tended to move more sharply than the broader market, which is typical of small and mid-cap biotech names and a factor that investors weighing the position size will usually take into account.MarketBeat

Partnered pipeline context with Johnson & Johnson

Beyond the share register and valuation, Protagonist Therapeutics remains closely tied to larger pharmaceutical partners in its pipeline, particularly Johnson & Johnson in the area of plaque psoriasis treatment.

A recent analysis of Johnson & Johnson by Zacks on September 18, 2026 highlighted that Johnson & Johnson markets the psoriasis drug Icotyde in partnership with Protagonist Therapeutics and described the partnered oral therapy as having the potential to significantly change plaque psoriasis treatment by offering a once-a-day pill.

In the same Zacks note, Johnson & Johnson expressed confidence in navigating broader challenges in its business, and the mention of Protagonist Therapeutics-partnered Icotyde underlines the strategic relevance of the smaller biotech to the larger pharmaceutical company’s growth plans in immune-mediated diseases.Zacks

For Protagonist Therapeutics stock, the partnership context matters because the market is assigning a high multiple to expected future revenue streams, and successful execution in programs like Icotyde is one of the key factors that could justify the current valuation and the analyst targets at and above the USD 147.13 consensus level.

Stock level and investor takeaway

As of September 17, 2026, the last completed trading day, Protagonist Therapeutics stock closed at USD 143.70 on Nasdaq, with the opening level on September 18, 2026 matching that figure and leaving the shares up strongly versus their 52-week low of USD 58.91 while still below the 52-week high of USD 160.81.MarketBeat

More news and analyses on Protagonist Therapeutics stock